{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:21:39Z","timestamp":1787541699863,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the impact of a patient support program (PSP) on the management of abemaciclib-related diarrhea in patients with hormone receptor-positive, human epidermal growth factor receptor 2\u2013negative (HR+\/HER2\u2212) metastatic breast cancer (MBC) and its influence on adherence and patient-reported outcomes in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a multicenter, prospective, observational Spanish study in patients with locally advanced or MBC receiving abemaciclib and enrolled in the PSP, assessed over 6\u00a0months. The primary endpoint was the proportion of patients reducing or discontinuing abemaciclib due to diarrhea. The secondary endpoints included diarrhea-related temporary interruptions, diarrhea management, adherence, HRQoL, and satisfaction with the PSP. Descriptive statistics were applied and treatment\u00a0modification endpoints were analyzed using Kaplan\u2013Meier.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 39 patients (median age: 58\u00a0years), with a median time since diagnosis of MBC of 2\u00a0months. Diarrhea occurred in 89.7% of patients, with grade 3 events in 7.7% and no grade\u2009\u2265\u20094 events. Nine patients (23.1%) experienced treatment modifications due to diarrhea; however, no permanent treatment discontinuations were reported. Loperamide (over 75% of patients) and dietary modifications were the most used self-care strategies. At week 24, results from the ad\u00a0hoc questionnaires showed that over 70% of the patients reported high satisfaction with all PSP aspects, and 80% were classified as treatment adherent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Episodes of diarrhea were mostly graded 1\u20132 and no patients discontinued abemaciclib due to diarrhea. Patients reported high satisfaction with abemaciclib PSP, good adherence, and favorable quality of life, supporting the use of PSP in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-026-04267-y","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:40:59Z","timestamp":1773315659000},"page":"3862-3871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical experience and satisfaction in patients with advanced breast cancer participating in the abemaciclib patient support program in Spain: a prospective observational study"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-6615","authenticated-orcid":false,"given":"Isabel","family":"Blancas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam Gonz\u00e1lez","family":"de la Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Fern\u00e1ndez","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Antol\u00edn","family":"Novoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Encarna Adrover","family":"Cebri\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo S\u00e1nchez","family":"Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Zamora","family":"Adelantado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Andr\u00e9s","family":"Conejero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"del Barco Berr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Atienza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Molero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"D\u00edaz-Cerezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"P\u00e9rez-Rambla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. J.","family":"P\u00e9rez-S\u00e1daba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Manso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"3","key":"4267_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4267_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4267_CR3","unstructured":"National Cancer Institute (NCI). Cancer stat facts: female breast cancer subtypes. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html (accessed 15 Dec 2025)."},{"issue":"6","key":"4267_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","volume":"27","author":"N Howlader","year":"2018","unstructured":"Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619\u201326.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"4267_CR5","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Therapeutic Positioning Report of abemaciclib (Verzenios\u00ae) in women with locally advanced or metastatic breast cancer. IPT 32\/2019 (Version 3, June 8, 2023). Available from https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-abemaciclib-Verzenios-cancer-mama.pdf (accessed 15 Dec 2025)."},{"issue":"2","key":"4267_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2024;35(2):159\u201382.","journal-title":"Ann Oncol"},{"issue":"5","key":"4267_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.","journal-title":"Breast Cancer Res"},{"issue":"13","key":"4267_CR8","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-14-0816","volume":"21","author":"T VanArsdale","year":"2015","unstructured":"VanArsdale T, Boshoff C, Arndt KT, Abraham RT. Molecular pathways: targeting the cyclin D-CDK4\/6 axis for cancer treatment. Clin Cancer Res. 2015;21(13):2905\u201310.","journal-title":"Clin Cancer Res"},{"key":"4267_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.","journal-title":"NPJ Breast Cancer"},{"issue":"25","key":"4267_CR10","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr.","year":"2017","unstructured":"Sledge GW Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875\u201384.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4267_CR11","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1002\/onco.13531","volume":"26","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Huober J, Garc\u00eda-S\u00e1enz JA, Masuda N, Sohn JH, Andre VAM, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021;26(1):e53\u201365.","journal-title":"Oncologist"},{"issue":"6","key":"4267_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s40271-022-00582-y","volume":"15","author":"JA Sacrist\u00e1n","year":"2022","unstructured":"Sacrist\u00e1n JA, Artime E, D\u00edaz-Cerezo S, Comellas M, P\u00e9rez-Carbonell L, Liz\u00e1n L. The impact of patient support programs in Europe: a systematic literature review. Patient. 2022;15(6):641\u201354.","journal-title":"Patient"},{"key":"4267_CR13","unstructured":"Lilly data on file: description and operational materials of the abemaciclib Patient Support Program in Spain."},{"issue":"4","key":"4267_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","volume":"16","author":"H Knobel","year":"2002","unstructured":"Knobel H, Alonso J, Casado JL, Collazos J, Gonz\u00e1lez J, Ruiz I, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002;16(4):605\u201313.","journal-title":"AIDS"},{"key":"4267_CR15","unstructured":"Functional Assessment of Chronic Illness Therapy\u2013Diarrhea (FACIT\u2011D). FACIT Measurement System. FACIT.org. Available from https:\/\/www.facit.org\/measures\/facit-d (accessed 15 Dec 2025)."},{"key":"4267_CR16","doi-asserted-by":"crossref","unstructured":"Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, et al. Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. NPJ Breast Cancer. 2024;10(1):58.","DOI":"10.1038\/s41523-024-00682-y"},{"issue":"31","key":"4267_CR17","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1080\/14796694.2024.2368455","volume":"20","author":"I Blancas","year":"2024","unstructured":"Blancas I, Grosjean J, Pedersini R, Buzzoni C, Sleilaty G, Molero A, et al. Abemaciclib for treating patients with HR+\/HER2- metastatic breast cancer: a real-world study in France, Italy and Spain. Future Oncol. 2024;20(31):2371\u201384.","journal-title":"Future Oncol"},{"key":"4267_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108488","author":"M Cejuela","year":"2023","unstructured":"Cejuela M, Gil-Torralvo A, Castilla M, Dom\u00ednguez-Cejudo M, Falc\u00f3n A, Benavent M, et al. Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24108488.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4267_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s44276-024-00070-w","volume":"2","author":"ML Gehrchen","year":"2024","unstructured":"Gehrchen ML, Berg T, Garly R, Jensen M-B, E\u00dfer-Naumann S, R\u00f8nlev JD, et al. Real-world effectiveness of CDK 4\/6 inhibitors in estrogen-positive metastatic breast cancer. BJC Reports. 2024;2(1):44.","journal-title":"BJC Reports"},{"key":"4267_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051775","author":"F Jacobs","year":"2023","unstructured":"Jacobs F, Agostinetto E, Solferino A, Torrisi R, Masci G, Santoro A, et al. Sticking to the rules: outcome and success rate of guideline-based diarrhea management in metastatic breast cancer patients treated with abemaciclib. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12051775.","journal-title":"J Clin Med"},{"key":"4267_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/20420986231224214","volume":"15","author":"F Martorana","year":"2024","unstructured":"Martorana F, San\u00f2 MV, Valerio MR, Fogli S, Vigneri P, Danesi R, et al. Abemaciclib pharmacology and interactions in the treatment of HR+\/HER2- breast cancer: a critical review. Ther Adv Drug Saf. 2024;15:20420986231224214.","journal-title":"Ther Adv Drug Saf"},{"key":"4267_CR22","unstructured":"EMA. Verzenios (abemaciclib): EPAR\u2014public assessment report 2017. Available from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/verzenios (accessed 15 Dec 2025)."},{"issue":"6","key":"4267_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000607","volume":"4","author":"M Kordes","year":"2019","unstructured":"Kordes M, Gerling M. Variations in the management of diarrhoea induced by cancer therapy: results from an international, cross-sectional survey among European oncologists. ESMO Open. 2019;4(6):e000607.","journal-title":"ESMO Open"},{"key":"4267_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejon.2016.12.008","volume":"26","author":"P Fox","year":"2017","unstructured":"Fox P, Darley A, Furlong E, Miaskowski C, Patiraki E, Armes J, et al. The assessment and management of chemotherapy-related toxicities in patients with breast cancer, colorectal cancer, and Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas: a scoping review. Eur J Oncol Nurs. 2017;26:63\u201382.","journal-title":"Eur J Oncol Nurs"},{"issue":"3","key":"4267_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10549-020-05798-w","volume":"183","author":"H Harder","year":"2020","unstructured":"Harder H, Shilling VM, May SF, Cella D, Schmid P, Fallowfield LJ. The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer. Breast Cancer Res Treat. 2020;183(3):629\u201338.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4267_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12094-018-02010-w","volume":"21","author":"JI Chacon Lopez-Muniz","year":"2019","unstructured":"Chacon Lopez-Muniz JI, de la Cruz Merino L, Gavila Gregori J, Martinez Duenas E, Oliveira M, Segui Palmer MA, et al. SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clin Transl Oncol. 2019;21(1):31\u201345.","journal-title":"Clin Transl Oncol"},{"issue":"12","key":"4267_CR27","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios C, Cortes J, de Azambuja E, DeMichele A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer\u2606. Ann Oncol. 2021;32(12):1475\u201395.","journal-title":"Ann Oncol"},{"issue":"6","key":"4267_CR28","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/bjc.2013.518","volume":"109","author":"TI Barron","year":"2013","unstructured":"Barron TI, Cahir C, Sharp L, Bennett K. A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer. Br J Cancer. 2013;109(6):1513\u201321.","journal-title":"Br J Cancer"},{"issue":"7","key":"4267_CR29","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/bjc.2013.116","volume":"108","author":"B Makubate","year":"2013","unstructured":"Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108(7):1515\u201324.","journal-title":"Br J Cancer"},{"issue":"2","key":"4267_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10549-018-05073-z","volume":"174","author":"R Paranjpe","year":"2019","unstructured":"Paranjpe R, John G, Trivedi M, Abughosh S. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2019;174(2):297\u2013305.","journal-title":"Breast Cancer Res Treat"},{"key":"4267_CR31","doi-asserted-by":"publisher","first-page":"1345482","DOI":"10.3389\/fphar.2024.1345482","volume":"15","author":"A Turcu-Stiolica","year":"2024","unstructured":"Turcu-Stiolica A, Udristoiu I, Subtirelu M-S, Gheorman V, Aldea M, Dumitrescu EA, et al. Digging in real-word electronic database for assessing CDK 4\/6 inhibitors adherence in breast cancer patients from Romania. Front Pharmacol. 2024;15:1345482.","journal-title":"Front Pharmacol"},{"issue":"9","key":"4267_CR32","doi-asserted-by":"publisher","first-page":"e1346","DOI":"10.1634\/theoncologist.2020-0084","volume":"25","author":"MP Goetz","year":"2020","unstructured":"Goetz MP, Mart\u00edn M, Tokunaga E, Park IH, Huober J, Toi M, et al. Health-related quality of life in MONARCH\u202f3: abemaciclib plus an aromatase inhibitor as initial therapy in HR+, HER2\u2212 advanced breast cancer. Oncologist. 2020;25(9):e1346\u201354.","journal-title":"Oncologist"},{"issue":"11","key":"4267_CR33","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1007\/s00520-015-2755-0","volume":"23","author":"D Perez","year":"2015","unstructured":"Perez D, Sharples KJ, Broom R, Jeffery M, Proctor J, Hinder V, et al. A randomised phase IIb trial to assess the efficacy of ReCharge ice cream in preventing chemotherapy-induced diarrhoea. Support Care Cancer. 2015;23(11):3307\u201315.","journal-title":"Support Care Cancer"},{"key":"4267_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193373","author":"G Ilie","year":"2024","unstructured":"Ilie G, Knapp G, Davidson A, Snow S, Dahn HM, MacDonald C, et al. The cancer patient empowerment program: a comprehensive approach to reducing psychological distress in cancer survivors, with insights from a mixed-model analysis, including implications for breast cancer patients. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16193373.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"4267_CR35","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1200\/JCO.2007.14.3248","volume":"26","author":"JE Bower","year":"2008","unstructured":"Bower JE. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol. 2008;26(5):768\u201377.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4267_CR36","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1007\/s00520-020-05334-y","volume":"28","author":"C Villarreal-Garza","year":"2020","unstructured":"Villarreal-Garza C, Platas A, Miaja M, Mesa-Chavez F, Garcia-Garcia M, Fonseca A, et al. Patients\u2019 satisfaction with a supportive care program for young breast cancer patients in Mexico: Joven & fuerte supports patients\u2019 needs and eases their illness process. Support Care Cancer. 2020;28(10):4943\u201351.","journal-title":"Support Care Cancer"},{"issue":"4","key":"4267_CR37","first-page":"157","volume":"3","author":"AM Geiger","year":"2000","unstructured":"Geiger AM, Mullen ES, Sloman PA, Edgerton BW, Petitti DB. Evaluation of a breast cancer patient information and support program. Eff Clin Pract. 2000;3(4):157\u201365.","journal-title":"Eff Clin Pract"},{"issue":"12","key":"4267_CR38","first-page":"656","volume":"31","author":"BA Jansen","year":"2023","unstructured":"Jansen BA, Bargon CA, Dinger TL, van den Goor M, Postma EL, Young-Afat DA, et al. Breast cancer patients\u2019 needs and perspectives on a one-on-one peer support program: quantitative and qualitative analyses. Support Care Cancer. 2023;31(12):656.","journal-title":"Support Care Cancer"},{"key":"4267_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1354377","volume":"14","author":"J Wolff","year":"2024","unstructured":"Wolff J, Seidel S, Wuelfing P, Lux MP, Zu Eulenburg C, Smollich M, et al. App-based support for breast cancer patients to reduce psychological distress during therapy and survivorship\u2014a multicentric randomized controlled trial. Front Oncol. 2024;14:1354377.","journal-title":"Front Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04267-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04267-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04267-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:09:49Z","timestamp":1787540989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04267-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4267"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04267-y","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study received ethical approval from the Hospital 12 de Octubre Ethics Committee on May 17 2022, and was registered following the Spanish regulation applicable to observational studies (GESTO-REEC 0080-2022-OBS, AEMPS num: 22-0087). Additionally, it received approval from the local review boards of the participating centers and complied with the principles outlined in the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Blancas has received grants and research support to the Institution from Agendia, AstraZeneca, Lilly, Pfizer, and Roche; honoraria as medical monitor from Medical Scientia Innovation Research (MEDSIR); Honoraria\/advisor colaboration\/fees as a consultant from Adelphi Targis, AstraZeneca, Bristol-Myers Squibb, Celgene, Cinfa, Daiichi Sankyo, Eisai, Gilead, Gr\u00fcnenthal, GSK, Lilly, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, TACTICS, Transworld Editors and Veracyte; support for attending meetings and\/or travel: AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Gilead, Lilly, Novartis, Pfizer, Pierre-Fabre and Roche. Dr. Gonz\u00e1lez de la Pe\u00f1a has received support for the present manuscript from Lilly. The institution of Dr. Fern\u00e1ndez Abad has received support for the present manuscript from Lilly. She has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Lilly, Novartis, and Astra Zeneca; payment for expert testimony from Astra Zeneca, MSD, and Novartis; support for attending meetings and\/or travel from Novartis and Gilead; and has participated in a Data Safety Monitoring Board or Advisory Board for Novartis and MSD. Dr. Antol\u00edn Novoa has received support for the present manuscript from Lilly. Dr. Adrover Cebri\u00e1n has received support (provision of study materials) for the present manuscript from Lilly; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Lilly. Dr. S\u00e1nchez Bayona has received consulting fees from Lilly, Novartis, Pfizer, AstraZeneca, Gilead Oncology; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Lilly, Pfizer, Novartis, AstraZeneca, Gilead, Roche, GSK; and support for attending meetings and\/or travel from AstraZeneca, Pfizer, Novartis, Roche, Gilead. Dr. Zamora Adelantado has received support for attending meetings and\/or travel from Lilly and Pfizer; and has participated on a Data Safety Monitoring Board or Advisory Board for MSD. Dr. Andr\u00e9s Conejero declares no conflict of interest. Dr. del Barco Berr\u00f3n declares no conflict of interest. Atienza is a Lilly employee and owner of Lilly shares. Molero is a Lilly employee and minor owner of Lilly shares. D\u00edaz-Cerezo is a Lilly employee and minor owner of Lilly shares. The employer of P\u00e9rez-Rambla is an independent research entity that has received fees for their contribution to the development of the project and scientific writing. The employer of P\u00e9rez-S\u00e1daba is an independent research entity that has received fees for their contribution to the development of the project and scientific writing. Dr. Manso declares no conflict of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}